164656-23-9 | Dutasteride

Packsize	Purity	Availability	Price	Discounted Price
5mg	95%	in stock	$88.00	$62.00
250mg	95%	in stock	$135.00	$94.00
1g	95%	in stock	$240.00	$168.00
5g	95%	in stock	$615.00	$431.00
25g	95%	in stock	$1,851.00	$1,296.00

Description

• Catalog Number: AA86644
• Chemical Name: Dutasteride
• CAS Number: 164656-23-9
• Molecular Formula: C27H30F6N2O2
• Molecular Weight: 528.5297191999998
• MDL Number: MFCD00937869
• SMILES: O=C1C=C[C@]2([C@H](N1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F)C)C
• NSC Number: 740477

Computed Properties

• Complexity: 964
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 7
• Heavy Atom Count: 37
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 2
• XLogP3: 5.4

Literature

• Why are most phospholipidosis inducers also hERG blockers?

  Archives of toxicology 20171201

• Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.

  Chemico-biological interactions 20170925

• Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20140120

• Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.

  European urology 20121101

• Contrast enhanced transrectal ultrasound for the detection of prostate cancer: a randomized, double-blind trial of dutasteride pretreatment.

  The Journal of urology 20121101

• A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.

  International journal of clinical practice 20121101

• Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.

  The Prostate 20121001

• Re: Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial.

  The Journal of urology 20121001

• Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia.

  Therapeutic advances in urology 20121001

• Benign prostatic hyperplasia (BPH) management in the primary care setting.

  The Canadian journal of urology 20121001

• Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.

  BJU international 20120901

• Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer.

  The Journal of urology 20120901

• Expectant management of localized prostate cancer--who, what, when, where and how?

  The Journal of urology 20120901

• [Add-on effect of dutasteride in patients with benign prostatic hyperplasia treated with alpha blocker : its effect on overactive bladder].

  Hinyokika kiyo. Acta urologica Japonica 20120901

• Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial.

  The Journal of clinical endocrinology and metabolism 20120801

• Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1).

  Journal of internal medicine 20120701

• Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity.

  Journal of lipid research 20120701

• Incomplete recovery of erectile function in rat after discontinuation of dual 5-alpha reductase inhibitor therapy.

  The journal of sexual medicine 20120701

• Re: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.

  The Journal of urology 20120701

• A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia.

  The oncologist 20120701

• Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia.

  World journal of urology 20120601

• Role of 5α-reductase inhibitors in prostate cancer prevention and treatment.

  Urology 20120601

• Words of wisdom: Re: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.

  European urology 20120601

• Promising therapies for treating and/or preventing androgenic alopecia.

  Skin therapy letter 20120601

• Blood donors on teratogenic drugs and donor deferral periods in a clinical situation.

  Vox sanguinis 20120501

• Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial.

  The Journal of urology 20120501

• [Prevention of uro-oncological diseases].

  Der Urologe. Ausg. A 20120501

• Dutasteride/tamsulosin: in benign prostatic hyperplasia.

  Drugs & aging 20120501

• [Chemoprevention of prostate cancer - a plea].

  Aktuelle Urologie 20120501

• High-grade prostatic intraepithelial neoplasia.

  Korean journal of urology 20120501

• Dutasteride and active surveillance of low-risk prostate cancer.

  Lancet (London, England) 20120428

• Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.

  BJU international 20120401

• Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20120401

• Combination pharmacological therapies for the management of benign prostatic hyperplasia.

  Drugs & aging 20120401

• α-blocker monotherapy and α-blocker plus 5-alpha-reductase inhibitor combination treatment in benign prostatic hyperplasia; 10 years' long-term results.

  Korean journal of urology 20120401

• What (if anything) to do about low-risk prostate cancer.

  Lancet (London, England) 20120324

• Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.

  Lancet (London, England) 20120324

• Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial.

  JAMA 20120307

• The role of 5α-reductase inhibition in men receiving testosterone replacement therapy.

  JAMA 20120307

• Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial.

  BJU international 20120301

• Re: Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the reduction by dutasteride of prostate cancer events trial.

  European urology 20120301

• Dutasteride for the treatment of prostate-related conditions.

  Expert opinion on drug safety 20120301

• Benign prostatic hyperplasia: from bench to clinic.

  Korean journal of urology 20120301

• Words of wisdom. Re: Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study.

  European urology 20120201

• Re: clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.

  The Journal of urology 20120201

• Re: comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).

  The Journal of urology 20120201

• Effect of prostatitis on lower urinary tract symptoms: retrospective analysis of prostate biopsy tissue.

  Korean journal of urology 20120201

• [Pharmacoeconomic evaluation of combination therapy with dutasteride and α1 blocker for treatment of benign prostatic hyperplasia in Japan].

  Hinyokika kiyo. Acta urologica Japonica 20120201

• Dutasteride monotherapy in men with serologic relapse following radical therapy for adenocarcinoma of the prostate: a pilot study.

  Urologic oncology 20120101

• Higher percentage of positive biopsy cores and Gleason score are associated with a greater degree of prostate gland shrinkage after neoadjuvant cytoreductive therapy.

  Brachytherapy 20120101

• Testosterone treatment fails to accelerate disease in a transgenic mouse model of spinal and bulbar muscular atrophy.

  Disease models & mechanisms 20120101

• Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension.

  Clinical drug investigation 20120101

• Re: Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.

  The Journal of urology 20120101

• Expression of apoptosis-regulating genes in the rat prostate following botulinum toxin type A injection.

  BMC urology 20120101

• The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases.

  Advances in urology 20120101

• The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice.

  PloS one 20120101

• Obesity, body composition, and prostate cancer.

  BMC cancer 20120101

• Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

  Drug design, development and therapy 20120101

• Kava components down-regulate expression of AR and AR splice variants and reduce growth in patient-derived prostate cancer xenografts in mice.

  PloS one 20120101

• Dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic enlargement.

  Drugs of today (Barcelona, Spain : 1998) 20120101

• Ask the doctor. I take Avodart for my enlarged prostate. But I heard that Avodart increases prostate cancer risk. Is that true? Should I quit taking Avodart?

  Harvard health letter 20120101

• Prostate cancers detected during 5α-reductase inhibitor use are smaller, de-differentiated, but confined when compared to controls.

  Journal of Cancer 20120101

• Do no harm: a case in point.

  Perspectives in biology and medicine 20120101

• Prostatic relaxation induced by loperamide is reduced in spontaneously hypertensive rats.

  TheScientificWorldJournal 20120101

• Prostate cancer - a biomarker perspective.

  Frontiers in endocrinology 20120101

• Current status of treatment of spinal and bulbar muscular atrophy.

  Neural plasticity 20120101

• A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk.

  Genetic epidemiology 20120101

• Comparison of α-blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia.

  The Journal of international medical research 20120101

• A multiscale, mechanism-driven, dynamic model for the effects of 5α-reductase inhibition on prostate maintenance.

  PloS one 20120101

• The REDUCE metagram: a comprehensive prediction tool for determining the utility of dutasteride chemoprevention in men at risk for prostate cancer.

  Frontiers in oncology 20120101

• Improved supersaturation and oral absorption of dutasteride by amorphous solid dispersions.

  Chemical & pharmaceutical bulletin 20120101

• The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study.

  Prostate cancer and prostatic diseases 20111201

• Diabetes and prostate cancer risk in the REDUCE trial.

  Prostate cancer and prostatic diseases 20111201

• What's wrong with chemoprevention of prostate cancer?

  The American journal of bioethics : AJOB 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function.

  The journal of sexual medicine 20111101

• A systematic review of the effects and mechanisms of preoperative 5α-reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia.

  Asian journal of andrology 20111101

• Dutasteride: high-grade prostate cancer. Risky in prostate cancer prevention.

  Prescrire international 20111101

• PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols.

  World journal of urology 20111001

• A pilot study of endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging changes with dutasteride in patients with low risk prostate cancer.

  BJU international 20111001

• Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study.

  The Journal of urology 20111001

• [Primary prevention of urologic tumors: prostate cancer].

  Der Urologe. Ausg. A 20111001

• Angioedema associated with dutasteride therapy.

  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20111001

• Macroautophagy is regulated by the UPR-mediator CHOP and accentuates the phenotype of SBMA mice.

  PLoS genetics 20111001

• Late-onset hypogonadism syndrome and lower urinary tract symptoms.

  Korean journal of urology 20111001

• Effect of Shifting from Combination Therapy to Monotherapy of α-Blockers or 5α-Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic Hyperplasia.

  Korean journal of urology 20111001

• [Role of 5 alpha-reductase inhibitors in the chemoprevention of prostate cancer].

  Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20111001

• Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110915

• National-wide data on the treatment of BPH in Korea.

  Prostate cancer and prostatic diseases 20110901

• Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.

  Urology 20110901

• [Prostate cancer].

  Der Urologe. Ausg. A 20110901

• [Prostate cancer. Current and practice-relevant news from urology in 2011].

  Der Urologe. Ausg. A 20110901

• Montelukast for symptom control of interstitial cystitis.

  The Annals of pharmacotherapy 20110901

• Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial.

  Applied health economics and health policy 20110901

• Editorial comment.

  Urology 20110901

• Changes in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results.

  Korean journal of urology 20110901

• Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia.

  International neurourology journal 20110901

• Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).

  BJU international 20110801

• Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.

  Urology 20110801

• The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.

  The New England journal of medicine 20110714

• Ethanol enhances neurosteroidogenesis in hippocampal pyramidal neurons by paradoxical NMDA receptor activation.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20110706

• Low serum testosterone levels are poor predictors of sexual dysfunction.

  BJU international 20110701

• Battling prostate cancer with 5-alpha-reductase inhibitors: a pyrrhic victory?

  Journal of general internal medicine 20110701

• Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.

  The Journal of urology 20110701

• Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia.

  Korean journal of urology 20110701

• Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin.

  Patient related outcome measures 20110701

• Development and characterization of dutasteride bearing liposomal systems for topical use.

  Current drug discovery technologies 20110601

• Chemoprevention of prostate cancer.

  Acta oncologica (Stockholm, Sweden) 20110601

• Current status of transurethral prostatectomy: a korean multicenter study.

  Korean journal of urology 20110601

• Targeting 5α-reductase for prostate cancer prevention and treatment.

  Nature reviews. Urology 20110531

• Gas chromatography/mass spectrometry based hair steroid profiling may reveal pathogenesis in hair follicles of the scalp.

  Rapid communications in mass spectrometry : RCM 20110515

• Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer.

  The Journal of steroid biochemistry and molecular biology 20110501

• The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study.

  BJU international 20110501

• [Non dietetic environmental risk factors in prostate cancer].

  Actas urologicas espanolas 20110501

• Biopsy misidentification identified by DNA profiling in a large multicenter trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110501

• The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the combination of avodart and tamsulosin (CombAT) study.

  BJU international 20110501

• Association of IL10, IL10RA, and IL10RB polymorphisms with benign prostate hyperplasia in Korean population.

  Journal of Korean medical science 20110501

• Inhibition of the M. tuberculosis 3β-hydroxysteroid dehydrogenase by azasteroids.

  Bioorganic & medicinal chemistry letters 20110415

• Association of polymorphisms in CYP19A1 and CYP3A4 genes with lower urinary tract symptoms, prostate volume, uroflow and PSA in a population-based sample.

  World journal of urology 20110401

• Re: Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the combination of avodart and tamsulosin trial.

  The Journal of urology 20110401

• Re: The Effects of Combination Therapy With Dutasteride and Tamsulosin on Clinical Outcomes in Men With Symptomatic Benign Prostatic Hyperplasia: 4-Year Results From the CombAT Study.

  The Journal of urology 20110401

• Designing smarter cancer prevention trials.

  Nature 20110324

• Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men: the results from the REDUCE study.

  Japanese journal of clinical oncology 20110301

• Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients.

  The journal of sexual medicine 20110301

• Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.

  BJU international 20110301

• Castration-resistant prostate cancer: targeted therapies and individualized treatment.

  The oncologist 20110301

• Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.

  European urology 20110201

• Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.

  European urology 20110201

• Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen.

  Cancer prevention research (Philadelphia, Pa.) 20110201

• Oral testosterone with and without concomitant inhibition of 5α-reductase by dutasteride in hypogonadal men for 28 days.

  The Journal of urology 20110201

• The effects of 5α-reductase inhibition on benign prostatic hyperplasia treated by photoselective vaporization prostatectomy with the 120 Watt GreenLight HPS laser system.

  Journal of the American College of Surgeons 20110201

• Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial.

  The Lancet. Neurology 20110201

• Dutasteride for spinal and bulbar muscular atrophy.

  The Lancet. Neurology 20110201

• Annual drug update: 2010 in review.

  The Nurse practitioner 20110201

• [Cost-effectiveness of the combination therapy of dutasteride and tamsulosin in the treatment of benign prostatic hyperlasia in Spain].

  Actas urologicas espanolas 20110201

• [Comment to: «Cost-Effectiveness of the combination therapy of dutasteride and tamsulosin in the treatment of benign prostatic hyperlasia in Spain»].

  Actas urologicas espanolas 20110201

• Dutasteride: novel milestones in prostate cancer chemoprevention.

  Drugs of today (Barcelona, Spain : 1998) 20110201

• Benign prostatic hyperplasia: An overview of existing treatment.

  Indian journal of pharmacology 20110201

• Re: Fritz H. Schröder, Monique J. Roobol. The REDUCE Trial. Eur Urol 2010;58:253-255.

  European urology 20110101

• The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.

  The Journal of urology 20110101

• Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer.

  Cancer causes & control : CCC 20110101

• Prostate cancer: Dutasteride improves accuracy of diagnosis but may not prevent cancer development.

  Nature reviews. Urology 20110101

• Specific pharmacokinetic aspects of the urinary tract.

  Handbook of experimental pharmacology 20110101

• [Dutasteride in the treatment of benign prostatic hyperplasia: an update].

  Zhonghua nan ke xue = National journal of andrology 20110101

• Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders.

  Current pharmaceutical design 20110101

• Methods to predict and lower the risk of prostate cancer.

  TheScientificWorldJournal 20110101

• Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.

  Journal of hematology & oncology 20110101

• How to reduce your cancer risk: mechanisms and myths.

  International journal of general medicine 20110101

• Chemopreventive effect of PSP through targeting of prostate cancer stem cell-like population.

  PloS one 20110101

• Chemoprevention of prostate cancer with nutrients and supplements.

  Cancer management and research 20110101

• Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia.

  Therapeutics and clinical risk management 20110101

• Alopecia: evaluation and treatment.

  Clinical, cosmetic and investigational dermatology 20110101

• Identification of novel functional inhibitors of acid sphingomyelinase.

  PloS one 20110101

• 5-α reductase inhibitors and prostate cancer prevention: where do we turn now?

  BMC medicine 20110101

• Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.

  Molecular cancer 20110101

• Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability.

  Patient preference and adherence 20110101

• Suppressive effects of the antiandrogen agent, chlormadinone acetate and the 5alpha-reductase inhibitor, dutasteride on prostate weight and intraprostatic androgen levels in rats.

  Arzneimittel-Forschung 20110101

• Finasteride and male fertility.

  Journal of human reproductive sciences 20110101

• [Combined dutasteride and tamsulosin].

  Urologia 20110101

• An update on the changing indications for androgen deprivation therapy for prostate cancer.

  Prostate cancer 20110101

• Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants - In vivo evidence.

  Journal of carcinogenesis 20110101

• Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention.

  PloS one 20110101

• Lifetime economic burden of prostate cancer.

  BMC health services research 20110101

• How to appraise the effectiveness of treatment.

  Indian journal of urology : IJU : journal of the Urological Society of India 20110101

• Understanding results: P-values, confidence intervals, and number need to treat.

  Indian journal of urology : IJU : journal of the Urological Society of India 20110101

• Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer.

  Drug, healthcare and patient safety 20110101

• Hormones and prostate carcinogenesis: Androgens and estrogens.

  Journal of carcinogenesis 20110101

• Oncogenic activation of ERG: A predominant mechanism in prostate cancer.

  Journal of carcinogenesis 20110101

• What's new in androgenetic alopecia: approvals, long-term safety data, cancer risk and treatment options for women.

  Journal of drugs in dermatology : JDD 20110101

• Pilot Study of 15 Patients Receiving a New Treatment Regimen for Androgenic Alopecia: The Effects of Atopy on AGA.

  ISRN dermatology 20110101

• Beyond the HPA Axis: Progesterone-Derived Neuroactive Steroids in Human Stress and Emotion.

  Frontiers in endocrinology 20110101

• Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy.

  Korean journal of urology 20101201

• Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml.

  Korean journal of urology 20101201

• Analysis of initial baseline clinical parameters and treatment strategy associated with medication failure in the treatment of benign prostatic hyperplasia in Korea.

  International neurourology journal 20101201

• [The effects of dutasteride on voiding and storage symptoms in men with benign prostatic hyperplasia].

  Hinyokika kiyo. Acta urologica Japonica 20101201

• The effect of short-term dutasteride intake in early-stage prostate cancer: analysis of 148 patients who underwent three-dimensional prostate mapping biopsy.

  Urology 20101101

• PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.

  The Journal of urology 20101101

• 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review.

  BJU international 20101101

• Comparative effect of finasteride and dutasteride on chromogranin A levels.

  Anticancer research 20101101

• [Effect of one month treatment with dutasteride on transurethral resection of the prostate].

  Actas urologicas espanolas 20101101

• Operating characteristics of a partial-block randomized crossover bioequivalence study for dutasteride, a drug with a long half-life: investigation through simulation and comparison with final results.

  Journal of clinical pharmacology 20101001

• Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.

  The Prostate 20101001

• The potent synthetic androgens, dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone, do not require 5α-reduction to exert their maximal androgenic effects.

  The Journal of steroid biochemistry and molecular biology 20101001

• Words of wisdom. Re: effect of dutasteride on the risk of prostate cancer.

  European urology 20101001

• Combined medical treatment using dutasteride and tamsulosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

  Expert opinion on pharmacotherapy 20101001

• Prostate cancer: A closer look at the initial results from the REDUCE trial.

  Nature reviews. Urology 20101001

• Active surveillance for favorable-risk prostate cancer: a short review.

  Korean journal of urology 20101001

• The different reduction rate of prostate-specific antigen in dutasteride and finasteride.

  Korean journal of urology 20101001

• Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer.

  Endocrine-related cancer 20100901

• Dutasteride and prostate cancer risk.

  Current urology reports 20100901

• Evolving role of 5-alpha reductase inhibitors in chemoprevention.

  Nature reviews. Clinical oncology 20100901

• Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole GL, Bostwick DG, Brawley OW, et al.

  European urology 20100901

• Prevention strategies in prostate cancer.

  Current oncology (Toronto, Ont.) 20100901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100901

• Dutasteride and prostate cancer.

  The New England journal of medicine 20100819

• Dutasteride and prostate cancer.

  The New England journal of medicine 20100819

• Dutasteride and prostate cancer.

  The New England journal of medicine 20100819

• Dutasteride and prostate cancer.

  The New England journal of medicine 20100819

• The REDUCE Trial.

  European urology 20100801

• Dutasteride reduces incident prostate cancer in men after negative prostate biopsy.

  Evidence-based medicine 20100801

• Can chemoprevention reduce the risk of prostate cancer?

  Clinical chemistry 20100801

• Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study.

  Journal of the American Academy of Dermatology 20100801

• Conference Report: Eighth Annual AACR International Conference on Frontiers in Cancer Prevention Research.

  Cancer prevention research (Philadelphia, Pa.) 20100801

• Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole GL, Bostwick DG, Brawley OW, et al. REDUCE Study Group. N Engl J Med 2010;362:1192-202.

  European urology 20100801

• Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole G, Bostwick D, Brawley O, et al. N Engl J Med 2010;362:1192-202.

  European urology 20100801

• Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.

  The Journal of urology 20100701

• Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.

  International journal of clinical practice 20100701

• The use of 5-alpha reductase inhibitors for the prevention of prostate cancer.

  Cancer biology & therapy 20100701

• Enzyme-linked immunosorbent assays for doping control of 5alpha-reductase inhibitors finasteride and dutasteride.

  Analytica chimica acta 20100625

• New tests for prostate cancer may be nearing the clinic.

  Journal of the National Cancer Institute 20100602

• Prostate needle biopsy quality in reduction by dutasteride of prostate cancer events study: worldwide comparison of improvement with investigator training and centralized laboratory processing.

  Urology 20100601

• Secretagogue type, sex-steroid milieu, and abdominal visceral adiposity individually determine secretagogue-stimulated cortisol secretion.

  European journal of endocrinology 20100601

• Male androgenetic alopecia.

  Expert opinion on pharmacotherapy 20100601

• Editorial comment.

  Urology 20100601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100601

• Testosterone replacement in prostate cancer survivors with hypogonadal symptoms.

  BJU international 20100501

• Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams.

  Urology 20100501

• Update on chemoprevention for prostate cancer.

  Current opinion in urology 20100501

• Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.

  The Journal of urology 20100501

• A practical guide to male hypogonadism in the primary care setting.

  International journal of clinical practice 20100501

• Dutasteride (Avodart) for prevention of prostate cancer.

  The Medical letter on drugs and therapeutics 20100419

• Effect of the dual 5alpha-reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia.

  BJU international 20100401

• Effect of dutasteride on the risk of prostate cancer.

  The New England journal of medicine 20100401

• Chemoprevention of prostate cancer.

  The New England journal of medicine 20100401

• The effect of intraprostatic chronic inflammation on benign prostatic hyperplasia treatment.

  Korean journal of urology 20100401

• [Treatment of benign prostate hyperplasia].

  Orvosi hetilap 20100321

• Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial.

  Urology 20100301

• Mechanism of action of bolandiol (19-nortestosterone-3beta,17beta-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activities.

  The Journal of steroid biochemistry and molecular biology 20100215

• Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention.

  Cancer research 20100215

• An overview on 5alpha-reductase inhibitors.

  Steroids 20100201

• Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH.

  World journal of urology 20100201

• Stromal-epithelial interactions are responsible for prostate tumor progression through an androgen-related mechanism.

  Cancer biology & therapy 20100201

• Chemoprevention of prostate cancer.

  The Urologic clinics of North America 20100201

• The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.

  European urology 20100101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100101

• RP-HPLC Method for the Estimation of Dutasteride in Tablet Dosage Form.

  Indian journal of pharmaceutical sciences 20100101

• Management of the adult with congenital adrenal hyperplasia.

  International journal of pediatric endocrinology 20100101

• Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promises.

  International journal of pediatric endocrinology 20100101

• Cancer biomarker discovery: the entropic hallmark.

  PloS one 20100101

• Dutasteride prevents the growth response to testosterone in benign and androgen-sensitive malignant prostate cells.

  International journal of clinical and experimental medicine 20100101

• Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

  BMJ (Clinical research ed.) 20100101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100101

• Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies.

  Health and quality of life outcomes 20100101

• Glutathione S-transferase (GST) gene variants and risk of benign prostatic hyperplasia: a report in a North Indian population.

  Asian Pacific journal of cancer prevention : APJCP 20100101

• Transdermal delivery of bioidentical progesterone using dutasteride (A 5α-reductase inhibitor): a pilot study.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20100101

• Evaluation of plasma enzyme activities using gas chromatography-mass spectrometry based steroid signatures.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091215

• Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone.

  Endocrine-related cancer 20091201

• Awareness of prostate cancer among patients and the general public: results of an international survey.

  Prostate cancer and prostatic diseases 20091201

• Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts.

  The Prostate 20091201

• Clinical features of spinal and bulbar muscular atrophy.

  Brain : a journal of neurology 20091201

• Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091115

• Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.

  The Prostate 20091101

• Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.

  BJU international 20091101

• Contemporary hair transplantation.

  Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 20091101

• The effect of dutasteride on the efficacy of photoselective vaporization of the prostate: results of a randomized, placebo-controlled, double-blind study (DOP trial).

  Urology 20091101

• Prostate cancer prevention (AUGUST 2009).

  Cleveland Clinic journal of medicine 20091101

• Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.

  The Canadian journal of urology 20091001

• Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.

  Clinical genitourinary cancer 20091001

• On call. My brother needed surgery for an enlarged prostate at age 60. I am a few months shy of my 50th birthday, and my urine stream is starting to slow down a bit. Is there anything I can do to avoid following in my brother's footsteps?

  Harvard men's health watch 20091001

• Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia.

  International journal of urology : official journal of the Japanese Urological Association 20090901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090901

• High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series.

  British journal of cancer 20090707

• Treatment of postmenopausal frontal fibrosing alopecia with oral dutasteride.

  Journal of the American Academy of Dermatology 20090701

• Is it worth the wait?

  BJU international 20090701

• A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.

  The Prostate 20090601

• Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study.

  Urology 20090601

• Androgens and hair loss.

  Current opinion in endocrinology, diabetes, and obesity 20090601

• Molecular profiles of finasteride effects on prostate carcinogenesis.

  Cancer prevention research (Philadelphia, Pa.) 20090601

• The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme?

  Canadian Urological Association journal = Journal de l'Association des urologues du Canada 20090601

• Finasteride to prevent prostate cancer: a new chapter.

  Harvard men's health watch 20090601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090601

• Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer.

  European urology 20090501

• Pharmacological approaches to reducing the risk of prostate cancer.

  European urology 20090501

• The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.

  Current opinion in urology 20090501

• Overview of pivotal studies for prostate cancer risk reduction, past and present.

  Urology 20090501

• Frontal fibrosing alopecia: treatment with oral dutasteride and topical pimecrolimus.

  Journal of the European Academy of Dermatology and Venereology : JEADV 20090501

• Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study.

  Urology 20090401

• Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.

  BJU international 20090401

• Prostate cancer: a serious disease suitable for prevention.

  BJU international 20090401

• [Assessment of recommended dose of dutasteride on Japanese men with benign prostatic hyperplasia: a randomized, double-blind, placebo-controlled, parallel-group, dose response study].

  Hinyokika kiyo. Acta urologica Japonica 20090401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090401

• Biodegradable braided poly(lactic-co-glycolic acid) urethral stent combined with dutasteride in the treatment of acute urinary retention due to benign prostatic enlargement: a pilot study.

  BJU international 20090301

• Aromatase and 5alpha-reductase inhibition during an exogenous testosterone clamp unveils selective sex steroid modulation of somatostatin and growth hormone secretagogue actions in healthy older men.

  The Journal of clinical endocrinology and metabolism 20090301

• Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study.

  BJU international 20090301

• Hair loss in women.

  Seminars in cutaneous medicine and surgery 20090301

• Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.

  Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 20090301

• The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.

  European urology 20090201

• Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy.

  The Journal of urology 20090201

• Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer.

  The journal of sexual medicine 20090201

• Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH.

  Prostate cancer and prostatic diseases 20090101

• 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.

  Prostate cancer and prostatic diseases 20090101

• Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy.

  Scandinavian journal of urology and nephrology 20090101

• The psychometric validation of a US English satisfaction measure for patients with benign prostatic hyperplasia and lower urinary tract symptoms.

  Health and quality of life outcomes 20090101

• Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate.

  Clinical interventions in aging 20090101

• Finasteride in the treatment of patients with benign prostatic hyperplasia: a review.

  Therapeutics and clinical risk management 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090101

• The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study.

  Prostate cancer and prostatic diseases 20090101

• Effects of short-term dutasteride and Serenoa repens on perioperative bleeding and microvessel density in patients undergoing transurethral resection of the prostate.

  Scandinavian journal of urology and nephrology 20090101

• Therapeutic options in the treatment of benign prostatic hyperplasia.

  Patient preference and adherence 20090101

• A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia.

  Indian journal of urology : IJU : journal of the Urological Society of India 20090101

• Effect of dutasteride on the expression of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and microvessel density in rat and human prostate tissue.

  Scandinavian journal of urology and nephrology 20090101

• Finasteride-its impact on sexual function and prostate cancer.

  Journal of cutaneous and aesthetic surgery 20090101

• Finasteride induced Gynecomastia: Case report and Review of the Literature.

  International journal of trichology 20090101

• Update on the management of prostate cancer with goserelin acetate: patient perspectives.

  Cancer management and research 20090101

• The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial.

  European urology 20081201

• Antipsychotic-like properties of 5-alpha-reductase inhibitors.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20081201

• The role of combination medical therapy in benign prostatic hyperplasia.

  International journal of impotence research 20081201

• 5-alpha reductase inhibitors and erectile dysfunction: the connection.

  The journal of sexual medicine 20081201

• Androgen deficiency and defective intracrine processing of dehydroepiandrosterone in salivary glands in Sjögren's syndrome.

  The Journal of rheumatology 20081101

• Association between 5-alpha reductase inhibition and risk of hip fracture.

  JAMA 20081008

• Dutasteride (Avodart) with tamsulosin (Flomax) for benign prostatic hyperplasia.

  The Medical letter on drugs and therapeutics 20081006

• Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals.

  The journal of sexual medicine 20081001

• Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity.

  Diabetes 20081001

• Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.

  Urology 20081001

• Medical treatments for male and female pattern hair loss.

  Journal of the American Academy of Dermatology 20081001

• Sex hormone influence on hepatitis in young male A/JCr mice infected with Helicobacter hepaticus.

  Infection and immunity 20080901

• In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5alpha-reductase inhibitors.

  The Journal of steroid biochemistry and molecular biology 20080901

• Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily.

  Clinical interventions in aging 20080901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080901

• Preventing prostate cancer: new analyses put finasteride back on the map.

  Journal of the National Cancer Institute 20080820

• Benign prostatic hyperplasia and lower urinary tract symptoms in African Americans and Latinos: treatment in the context of common comorbidities.

  The American journal of medicine 20080801

• Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management.

  International journal of clinical practice 20080701

• Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.

  The Journal of urology 20080701

• The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.

  Expert review of anticancer therapy 20080701

• By the way, doctor. I have been taking Avodart for my BPH, along with Flomax, but finasteride may be less expensive. Should I switch?

  Harvard health letter 20080701

• The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men.

  The Journal of urology 20080601

• Androgens and prevention of prostate cancer.

  Current opinion in endocrinology, diabetes, and obesity 20080601

• A connection between the mitochondrial permeability transition pore, autophagy, and cerebral amyloidogenesis.

  Journal of proteome research 20080601

• [Dutasteride in the treatment of hormone refractory prostate cancer].

  Minerva urologica e nefrologica = The Italian journal of urology and nephrology 20080601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080601

• 5-Alpha reductase inhibitors in men with an enlarged prostate: an evaluation of outcomes and therapeutic alternatives.

  The American journal of managed care 20080501

• Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.

  The American journal of managed care 20080501

• Comparative analysis of alpha-blocker utilization in combination with 5-alpha reductase inhibitors for enlarged prostate in a managed care setting among Medicare-aged men.

  The American journal of managed care 20080501

• Cost comparison of finasteride and dutasteride for enlarged prostate in a managed care setting among Medicare-aged men.

  The American journal of managed care 20080501

• The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.

  The Journal of urology 20080401

• Current status of 5alpha-reductase inhibitors in the treatment of benign hyperplasia of prostate.

  Indian journal of medical sciences 20080401

• 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.

  Best practice & research. Clinical endocrinology & metabolism 20080401

• A review of hormonal therapy for female pattern (androgenic) alopecia.

  Dermatology online journal 20080315

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080301

• Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.

  European urology 20080201

• The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.

  The Journal of urology 20080201

• Dutasteride prior to contrast-enhanced colour Doppler ultrasound prostate biopsy increases prostate cancer detection.

  European urology 20080101

• Dutasteride significantly improves quality of life measures in patients with enlarged prostate.

  Prostate cancer and prostatic diseases 20080101

• Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey.

  International journal of clinical practice 20080101

• Pharmacokinetics and pharmacodynamics of oral testosterone enanthate plus dutasteride for 4 weeks in normal men: implications for male hormonal contraception.

  Journal of andrology 20080101

• Nanomilled oral testosterone plus dutasteride effectively normalizes serum testosterone in normal men with induced hypogonadism.

  Journal of andrology 20080101

• Novel concepts in androgen receptor blockade.

  Cancer journal (Sudbury, Mass.) 20080101

• Dutasteride: a review of its use in the management of prostate disorders.

  Drugs 20080101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080101

• Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease.

  BMC neurology 20080101

• [The experience in dutasteride use before transurethral prostatic resection for large adenoma].

  Urologiia (Moscow, Russia : 1999) 20080101

• Strategies for prostate cancer prevention: Review of the literature.

  Indian journal of urology : IJU : journal of the Urological Society of India 20080101

• Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.

  Contemporary clinical trials 20071101

• Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.

  Contemporary clinical trials 20071101

• Post-coital gross hematuria: an unusual presentation of benign prostatic hyperplasia.

  Asian journal of andrology 20071101

• Decreased efficiency of potassium-titanyl-phosphate laser photoselective vaporization prostatectomy with long-term 5 alpha-reductase inhibition therapy: is it true?

  Urology 20071101

• [Gynecomastia and dutasteride].

  Medicina clinica 20071027

• Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines.

  Investigational new drugs 20071001

• Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer.

  The Journal of urology 20071001

• Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate.

  Andrologia 20071001

• Impurity profile study of dutasteride.

  Die Pharmazie 20071001

• Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial.

  The Journal of urology 20070901

• Chemoprevention of prostate cancer: agents and study designs.

  The Journal of urology 20070901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070901

• [Benign prostatic hyperplasia: medical therapy].

  MMW Fortschritte der Medizin 20070816

• 5alpha-reductase inhibition for men with enlarged prostate.

  Journal of the American Academy of Nurse Practitioners 20070801

• Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride.

  The Prostate 20070701

• Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling.

  The Journal of urology 20070601

• Female pattern hair loss: current treatment concepts.

  Clinical interventions in aging 20070601

• The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men.

  The Journal of clinical endocrinology and metabolism 20070501

• Re: The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.

  The Journal of urology 20070501

• Benign prostatic hyperplasia: when to 'watch and wait,' when and how to treat.

  Cleveland Clinic journal of medicine 20070501

• The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.

  The Journal of urology 20070401

• A review of phase III clinical trials of prostate cancer chemoprevention.

  Annals of the Royal College of Surgeons of England 20070401

• Dutasteride improves male pattern hair loss in a randomized study in identical twins.

  Journal of cosmetic dermatology 20070301

• Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride.

  BJU international 20070301

• A review of combination therapy in patients with benign prostatic hyperplasia.

  Clinical therapeutics 20070301

• Update on the use of dutasteride in the management of benign prostatic hypertrophy.

  Clinical interventions in aging 20070301

• Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH).

  Therapeutics and clinical risk management 20070301

• [Dutasteride-induced gynecomastia].

  Medicina clinica 20070224

• Medical therapy for benign prostatic hyperplasia--present and future impact.

  The American journal of managed care 20070201

• A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.

  The American journal of managed care 20070201

• Differences in alpha blocker usage among enlarged prostate patients receiving combination therapy with 5 ARIs.

  The American journal of managed care 20070201

• Finasteride versus dutasteride: a real-world economic evaluation.

  The American journal of managed care 20070201

• Medical treatment of benign prostatic hyperplasia.

  Postgraduate medical journal 20070201

• Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma.

  Histology and histopathology 20070101

• The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.

  Prostate cancer and prostatic diseases 20070101

• Prevention of prostate cancer: more questions than data.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20070101

• Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate.

  Archives of andrology 20070101

• A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.

  Clinical therapeutics 20070101

• Long-term cost analysis of treatment options for benign prostatic hyperplasia in Norway.

  Scandinavian journal of urology and nephrology 20070101

• Method for evaluating prediction models that apply the results of randomized trials to individual patients.

  Trials 20070101

• Identification of the patient with enlarged prostate: diagnosis and guidelines for management.

  Osteopathic medicine and primary care 20070101

• Randomised controlled trials for evaluating the prescribing impact of information meetings led by pharmacists and of new information formats, in General Practice in Italy.

  BMC health services research 20070101

• [Dutasteride--an inhibitor of 5alpha-reductase of type I and II--in the treatment of patients with prostatic adenoma. What is the latest news?].

  Urologiia (Moscow, Russia : 1999) 20070101

• Pathogenesis of prostate cancer and hormone refractory prostate cancer.

  Indian journal of urology : IJU : journal of the Urological Society of India 20070101

• Treatment algorithm in hormone-resistant prostate cancer: Practical guidelines.

  Indian journal of urology : IJU : journal of the Urological Society of India 20070101

• Acute urinary retention in benign prostatic hyperplasia: Risk factors and current management.

  Indian journal of urology : IJU : journal of the Urological Society of India 20070101

• Emphysematous prostatitis in renal transplant.

  Indian journal of urology : IJU : journal of the Urological Society of India 20070101

• Does dutasteride reduce perioperative blood loss and postoperative complications after transurethral resection of the prostate?

  Indian journal of urology : IJU : journal of the Urological Society of India 20070101

• The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.

  Journal of the American Academy of Dermatology 20061201

• Comorbid LUTS and erectile dysfunction: optimizing their management.

  Current medical research and opinion 20061201

• Role of 5 alpha-reductase inhibitors in the management of prostate cancer.

  Clinical interventions in aging 20061201

• The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study.

  The Prostate 20061101

• Testosterone levels in benign prostatic hyperplasia: sexual function and response to therapy with dutasteride.

  Nature clinical practice. Urology 20061001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20061001

• Benign prostatic hypertrophy: update on drug therapy.

  Canadian family physician Medecin de famille canadien 20060910

• The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.

  The Journal of urology 20060901

• Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.

  The Journal of urology 20060901

• Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.

  Nature clinical practice. Urology 20060901

• [Drug therapy for benign prostatic syndrome (BPS)].

  Aktuelle Urologie 20060901

• Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment.

  The Journal of steroid biochemistry and molecular biology 20060801

• Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060701

• Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice.

  BJU international 20060701

• Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy.

  Urology 20060701

• Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines.

  Cancer 20060615

• Actions of 5alpha-reductase inhibitors on the epididymis.

  Molecular and cellular endocrinology 20060516

• Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.

  The Journal of urology 20060501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060501

• Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.

  The Journal of clinical endocrinology and metabolism 20060401

• Impact of medical treatments for benign prostatic hyperplasia on sexual function.

  BJU international 20060401

• Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?

  BJU international 20060401

• Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.

  The Annals of pharmacotherapy 20060401

• BPH: epidemiology and comorbidities.

  The American journal of managed care 20060401

• Treatment and pharmacologic management of BPH in the context of common comorbidities.

  The American journal of managed care 20060401

• Update on prostate cancer chemoprevention.

  Pharmacotherapy 20060301

• Dutasteride, cantharidin, atopiclair, cetuximab, sirolimus, AC-11 and dimericine reviewed in brief.

  Journal of drugs in dermatology : JDD 20060201

• Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia.

  BJU international 20060101

• Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men.

  Journal of andrology 20060101

• Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia.

  Urology 20060101

• By the way, doctor. I developed acute urinary retention after having a pacemaker put in. I'm a 90-year-old man and in pretty good shape considering my age, but I'd rather not have any more procedures. What are my options?

  Harvard health letter 20060101

• Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.

  Clinical therapeutics 20060101

• Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.

  Current pharmaceutical design 20060101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060101

• Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor.

  Current topics in medicinal chemistry 20060101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060101

• Efficacy and tolerability of the dual 5alpha-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men.

  Prostate cancer and prostatic diseases 20060101

• Chemopreventive trials in urologic cancer.

  Reviews in urology 20060101

• A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.

  PloS one 20060101

• [Treatment of prostatic adenoma patients with inhibitor of 5-alpha-reductase of type I and II avodart (dutasteride)].

  Urologiia (Moscow, Russia : 1999) 20060101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20051201

• [Effect of dutasteride on reduction of intraoperative bleeding related to transurethral resection of the prostate].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20051201

• [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20051201

• Phase III prostate cancer prevention trials: are the costs justified?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051110

• Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.

  The Journal of urology 20051101

• Effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist on spermatogenesis and intratesticular steroid levels in normal men.

  The Journal of clinical endocrinology and metabolism 20051001

• Effect of dutasteride therapy on Doppler US evaluation of prostate: preliminary results.

  Radiology 20051001

• Evaluation and medical management of benign prostatic hyperplasia.

  Mayo Clinic proceedings 20051001

• [Prevention of prostate cancer].

  Deutsche medizinische Wochenschrift (1946) 20050909

• Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.

  BJU international 20050901

• [Novel therapeutics strategies in benign hypertrophy of prostate management].

  Revue medicale de Bruxelles 20050901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050901

• Selecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia.

  BJU international 20050801

• Combined inhibition of types I and II 5 alpha-reductase selectively augments the basal (nonpulsatile) mode of testosterone secretion in young men.

  The Journal of clinical endocrinology and metabolism 20050701

• Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).

  European urology 20050601

• Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.

  Journal of molecular endocrinology 20050601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050601

• Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study.

  The Journal of clinical endocrinology and metabolism 20050501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050501

• RE: Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.

  The Journal of urology 20050401

• Chemoprevention of prostate cancer.

  Critical reviews in oncology/hematology 20050401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050401

• Dutasteride: a novel dual inhibitor of 5alpha-reductase for benign prostatic hyperplasia.

  Expert opinion on pharmacotherapy 20050201

• Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist.

  The Journal of clinical endocrinology and metabolism 20050101

• Chemoprevention using dutasteride: the REDUCE trial.

  Current opinion in urology 20050101

• Two for the price of one?

  British journal of pharmacology 20050101

• The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.

  Urology 20050101

• [Dutasteride (Avodart): a novel 5-alpha reductase inhibitor for treatment of benign prostate hypertrophy].

  Revue medicale de Bruxelles 20050101

• Noninvasive management of lower urinary tract symptoms and sexual dysfunction associated with benign prostatic hyperplasia in the primary care setting.

  Comprehensive therapy 20050101

• Effective treatment of female androgenic alopecia with dutasteride.

  Journal of drugs in dermatology : JDD 20050101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050101

• [Prostate carcinoma: can 5-alpha reductase inhibitors prevent it?].

  Krankenpflege Journal 20050101

• Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase.

  Reviews in urology 20050101

• Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia.

  Core evidence 20050101

• Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.

  The Journal of urology 20041201

• [Use of 5-alpha-reductase inhibitors in the prevention of prostate cancer].

  Annales d'urologie 20041201

• [Dutasteride: main results in the treatment of benign prostatic hyperplasia].

  Annales d'urologie 20041201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20041101

• Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.

  European urology 20041001

• Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.

  The Journal of urology 20041001

• Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.

  The Journal of urology 20041001

• Uropharmacology: current and future strategies in the treatment of erectile dysfunction and benign prostate hyperplasia.

  International journal of clinical pharmacology and therapeutics 20041001

• Selective and rapid liquid chromatography-tandem mass spectrometry assay of dutasteride in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040925

• Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.

  The Journal of urology 20040901

• Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician.

  BJU international 20040901

• Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.

  Urology 20040901

• The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data.

  Current urology reports 20040801

• Dutasteride: a potent dual inhibitor of 5-alpha-reductase for benign prostatic hyperplasia.

  Drugs of today (Barcelona, Spain : 1998) 20040801

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040601

• Preventing diseases of the prostate in the elderly using hormones and nutriceuticals.

  The aging male : the official journal of the International Society for the Study of the Aging Male 20040601

• [Chemoprevention of prostate cancer].

  Der Urologe. Ausg. A 20040501

• Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.

  The Journal of clinical endocrinology and metabolism 20040501

• Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.

  Urology 20040401

• An update on the use of 5alpha-reductase inhibitors.

  Drugs of today (Barcelona, Spain : 1998) 20040301

• Chemotherapeutic prevention studies of prostate cancer.

  The Journal of urology 20040201

• Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.

  The Prostate 20040201

• Hair loss remedies--separating fact from fiction.

  Cutis 20040201

• A current review of medical therapy for benign prostatic hyperplasia.

  The Journal of the American Osteopathic Association 20040201

• Benign prostatic hyperplasia progression and its impact on treatment.

  Current opinion in urology 20040101

• Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride.

  Journal of andrology 20040101

• 5alpha-reductase: history and clinical importance.

  Reviews in urology 20040101

• The Clinical Benefits of Dutasteride Treatment for LUTS and BPH.

  Reviews in urology 20040101

• Comparison of clinical trials with finasteride and dutasteride.

  Reviews in urology 20040101

• The Use of Nomograms for Selecting BPH Candidates for Dutasteride Therapy.

  Reviews in urology 20040101

• Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride.

  European urology 20031001

• Dutasteride: a new 5-alpha reductase inhibitor for men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.

  International journal of clinical practice 20031001

• The Finnish version of The National Institutes Of Health Chronic Prostatitis Symptom Index correlates well with the visual pain scale: translation and results of a modified linguistic validation study.

  BJU international 20030801

• Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.

  BJU international 20030801

• [The tested combination is recommended. Are 5-alpha reductase inhibitors interchangeable?].

  MMW Fortschritte der Medizin 20030710

• Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia.

  European urology 20030701

• Drug available to treat enlarged prostate.

  Mayo Clinic health letter (English ed.) 20030701

• Dutasteride (Avodart): new 5-alpha-reductase inhibitor for treating BPH.

  Urologic nursing 20030601

• The role of dihydrotestosterone in benign prostatic hyperplasia.

  Urology 20030401

• [Dual 5-alpha reductase inhibitors in BPH (benign prostatic hyperplasia). Already after 1 month prostate shrinks].

  MMW Fortschritte der Medizin 20030227

• 5 alpha-reductase inhibitors: what's new?

  Current opinion in urology 20030101

• Testosterone metabolism in human skin cells in vitro and its interaction with estradiol and dutasteride.

  Skin pharmacology and applied skin physiology 20030101

• Dutasteride.

  Drugs & aging 20030101

• Dutasteride (Avodart) for benign prostatic hyperplasia.

  The Medical letter on drugs and therapeutics 20021223

• [Hormonal therapy for benign prostatic hyperplasia].

  Nihon rinsho. Japanese journal of clinical medicine 20021201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021201

• Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.

  Urology 20020901

• [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].

  Der Urologe. Ausg. A 20020901

• Gateways to Clinical Trials.

  Methods and findings in experimental and clinical pharmacology 20020901

• Managing benign prostatic hyperplasia.

  American family physician 20020701

• Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.

  World journal of urology 20020401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20020101

• Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5alpha-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat.

  Biochemical pharmacology 20011001

• Mass spectral fragmentation reactions of a therapeutic 4-azasteroid and related compounds.

  Journal of the American Society for Mass Spectrometry 20010401

• IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN). The nomenclature of steroids. Recommendations 1989.

  European journal of biochemistry 19891222